AACR 2022 | HER2-low status as a therapeutic target in advanced breast cancer

Changchuan Jiang, MD, MPH, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses opportunities in the novel field of HER2-low breast cancer. Approximately half of breast cancers have low HER2 expression, representing an exciting new target. Results from the DESTINY-Breast04 Phase III trial (NCT03734029) have shown trastuzumab deruxtecan demonstrated a statistically significant improvement in both progression-free survival (PFS) and overall survival (OS) in patients with HER2-low unresectable and/or metastatic breast cancer regardless of hormone receptor (HR) status versus physician’s choice of chemotherapy. It is hoped that these promising results could translate into effective therapies in earlier-line settings. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.